Prospective study of icotinib concurrent IMRT in patients with inoperable stage non III -small cell lung cancer

To evaluate the safety profile and efficacy of icotinib concurrent with intensity modulated conformal radiotherapy (IMRT) in previously untreated patients with inoperable Stage non III -small cell lung cancer (NSCLC). 90 patients were enrolled in this prospective study. All patients were assessed for toxicity, and 78 patients were available for efficacy. 24 patients were treated with icotinib concurrent IMRT with curative intent. The primary endpoints were overall survival (OS). The secondary endpoints included progression free survival (PFS), local control rate and acute toxicity. Loss of appetite, leucopenia, rash, pulmonary toxicities were acceptable and manageable. Severe adverse events included pain (Grade 4, 12.5%) and leucopenia (Grade 4, 4.17%), rash (Grade 4, 4.17%). With a median follow-up of 321 days, a local control rate of 95.8% was achieved for thoracic tumor. Overall survival and median PFS were 377 days, 289 days. The current experimental data suggested that icotinib concomitant IMRT was effective and safe for patients with advanced NSCLC as first-line regimen.